Recent Finacing
Recent Raise
Padlock Therapeutics develops PAD-directed therapeutics that inhibit protein-arginine deiminase enzymes to reduce citrullinated autoantigen and proinflammatory mediator production for autoimmune indications including rheumatoid arthritis, lupus, and multiple sclerosis.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor